seen from United States
seen from United Kingdom
seen from United States
seen from United States
seen from Netherlands
seen from United States
seen from United States
seen from United States
seen from Türkiye
seen from Russia
seen from United States
seen from United States
seen from China
seen from Türkiye
seen from United States
seen from Canada
seen from United States
seen from United States
seen from Yemen
seen from United States
Epigenetics Market Competitive Landscape, Differentiation Strategies and Forecast to 2033
Epigenetics Industry worth $4.3 billion by 2028, with a CAGR of 18.3%
The report "Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Instrument, Software), Method (DNA Methylation), Technique (NGS, PCR, Mass Spectrometry), Application (Oncology, Immunology) - Global Forecast to 2028 ", is projected to reach USD 4.3 billion by 2028 from USD 1.8 billion in 2023, at a CAGR of 18.3% during the forecast period of 2023 to 2028.
Browse 367 market data Tables and 45 Figures spread through 366 Pages and in-depth TOC on "Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Instrument, Software), Method (DNA Methylation), Technique (NGS, PCR, Mass Spectrometry), Application (Oncology, Immunology) - Global Forecast to 2028 " View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/epigenetics-technologies-market-896.html
The global epigenetics market is expected to grow at a CAGR of 18.3 % during the forecast period. The growth of the market is projected to be driven by factors such as as rising investment in R&D, declining sequencing cost & time, favorable government initiatives & funding for epigenetics research, advancement in technology for epigenetic research and increasing demand for epigenetic-based therapeutics.
The kits & reagents segment segment is expected to have the dominant share of the epigenetics market in 2022.
Based on technology, the global epigenetics market is segmented into kits & reagents, enzymes, instruments and accessories, software, and service. The kits & reagents is further segmented into antibodies, chip-sequencing kits & reagents, whole-genome amplification kits & reagents and 5-HMC & 5-MC Analysis kits & reagents, histones and other kits & reagents. In 2022, the Antibodies segment held the largest share of the epigenetics market. The rising adoption of antibodies in detection, identification, and alteration/modification of proteins followed by their role in monitoring cell regulation & expression are the driving factor for the growth of the antibodies segment during the forecast period.
The DNA methylation segment accounted for the largest share of the method segment in the epigenetics market in 2022.
Based on disease indication, the epigenetics market is segmented DNA methylation, histone modifications, and other methods (non-coding RNA and chromatin remodelling). The DNA methylation segment is anticipated to grow at significant CAGR during the forecast period owing to factor such as efficacy of the DNA methylation technique in oncology studies.
The Asia Pacific region is the fastest-growing region of the epigenetics market in 2022.
The Asia Pacific is accounted to be the fastest-growing segment of the market. The growth of the epigenetics markets in the region is driven by the expanding international presence of domestic players by adopting strategic agreements, partnerships, and collaborations and Improving healthcare infrastructure in developing Asia Pacific economies.
Key Players
The epigenetics market is moderately consolidated, with a small number of players competing for market shares. Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Active Motif, Inc. (US), Bio-Rad Laboratories Inc. (US), Promega Corporation (US), Revvity (US), Qiagen (Germany), New England Biolabs (US), Zymo Research Corporation (US), Diagenode SA (US), F. Hoffmann-La Roche Ltd (Switzerland) and Epigentek Group Inc. (US) are some of the leading players in this market. Most companies in the market focus on organic and inorganic growth strategies, such as product launches, expansions, acquisitions, partnerships, and agreements, to increase their product offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.
Epigenetic mechanisms are being linked to a growing number of chronic diseases and disorders, including cardiovascular diseases, autoimmun...
The growth of the epigenetics market is expected to be driven by the decrease in the cost of sequencing, the global increase in the application of next-generation sequencing, and the advancement of the products. Among all applications of epigenetics, oncology accounted for the largest share in 2020, holding 52.01% of the market.
The epigenetics market to be one of the highest booming markets, and the global market is predicted to grow at a CAGR of 17.11% during the forecast period 2021-2031.
The epigenetics industry has tremendous growth potential due to highly opportunistic trends like the quick acceptance of epigenetics in the treatment of cancer, heart disease, and liver cirrhosis in healthcare settings. The rise of epigenetics has resulted in a growing need for testing assays developed by firms in this sector to enable improved outcomes on the rising occurrence of cancer.
Epigenetics Market: An Exclusive Study On Upcoming Trends And Growth Opportunities
The global epigenetics market size is expected to reach USD 22.05 billionby 2025, according to a new study by Grand View Research, Inc., progressing at a CAGR of 19.7% during the forecast period. The growing prevalence of cancer and other diseases worldwide with an epigenetic modification base is expected to drive the market during the forecast period.
Diagnostic companies are coming up with new products such as antibodies specific for the detection of modifications and new upgraded kits for easy and efficient detection of biomarkers. This is estimated to attract pharmaceutical companies to collaborate for the development of therapeutic drugs, which will work in favor of the market.
The presence of pipeline drugs and their expected commercialization is anticipated to boost the growth of the market. For instance, Ramucirumab (Cyramza) by Eli Lilly and Company was approved by the FDA for use in combination with Folfiri for the treatment of patients with metastatic colorectal cancer.
Technology advancements in the epigenetics industry are majorly focusing on the detection of methylation markers related to cancer development. For instance, Epi proLung BL Reflex Assay by Epigenomics helps in the diagnosis of lung cancer by determining methylation of SHOX2 biomarker gene.
Browse full report with Table of Content @ https://bit.ly/3FnMEpa
Epigenetics Market Report Highlights
• On the basis of product, reagents held the largest share in the market in 2017. They are projected to amount to approximately USD 7.06 billion by 2025 owing to increasing R&D activities in the field of epigenetics
The kits segment is expected to post a CAGR of over 20.0% due to the need for rapid and accurate detection techniques
• DNA methylation, on the basis of technology, held the leading revenue share in the market in 2017, accounting for just over 47.0%. The rapid adoption of advanced techniques such as methylation-sensitive PCR (MSP) to improve diagnostics efficiency is poised to bolster the growth of the segment
• North America commanded the leading position in the global arena with a share of 40.0% in 2017. The growth of the regional market can be attributed to the increasing prevalence of cancer and growing collaborations between large pharmaceutical firms for the development of improved therapeutics
• Asia Pacific is estimated to register a noteworthy CAGR of 22.1% during the forecast period owing to the presence of a large target population coupled with high unmet clinical needs
• Some of the major players of epigenetics market are Illumina; Abcam; Diagenode; Thermo Fisher Scientific; Merck; Zymo research; Qiagen; CellCentric Ltd; Chroma Therapeutics Ltd; Eisai Co. Ltd; Novartis International AG; Oncolys Biopharma Inc.; Syndax Pharmaceuticals, Inc.; Valirx Plc; and Sigma-Aldrich Corporation
• Extensive R&D initiatives for the development of novel drugs and the presence of strong product pipeline are expected to further boost market growth over the forecast period.
For Requesting a Sample Copy of This Report, Please Visit @ https://bit.ly/3zQeBVs
Epigenetics Market Growth Forecasts with Upcoming Opportunities by 2025
According to a new market research study titled ‘Epigenetics Market to 2025 - Global Analysis and Forecasts by Product, Technology, Application and End User. The global epigenetics market is expected to reach US$ 2,611.57 Mn in 2025 from US$ 991.45 in 2017. The market is estimated to grow with a CAGR of 13.6% from 2018-2025. The report highlights the trends prevalent in the global epigenetics market and the factors driving the market along with those that act as deterrents to its growth.
Global epigenetics market, based on technology was segmented histone modification, DNA methylation and other technologies. In 2017, DNA methylation segment held the largest share of the market, by technology. The largest share of the DNA methylation is primarily owing to its ability to develop therapies for diseases including cancer, lupus, muscular dystrophy and various congenital defects and also it helps to prevent conditions that develop during embryonic development such as, abnormal methylation of the X-chromosome and gene imprinting.
The market for epigenetics is expected to grow as declining prices of sequencing, increasing prevalence of cancer, funds & grants provided by government bodies are expected to fuel the market growth during the forecast period. In addition, promising precise treatments by neurogenetics are likely to have a positive impact on the growth of the market in the coming years.
The major players operating in the epigenetics market are Merck KGaA, Thermo Fisher Scientific Inc., ABCAM Plc, Agilent Technologies, Active Motif, Qiagen, Bio-Rad Laboratories, Inc., Perkinelmer Inc., New England Biolabs (NEB), and Illumina Inc. For instance, in February, 2018, QIAGEN launches epigenetic breast cancer test in Europe. It is the first clinically validated DNA methylation assay that helps predict the response to anthracycline-based chemo by certain high-risk breast cancer patients.
The report segments the global epigenetics market as follows:
Global epigenetics Market - By Product
· Reagents
· Kits
· Enzymes
· Instruments & Consumables
· Bioinformatics Tools
Global epigenetics Market - By Technology
· Histone Modification
· DNA Methylation
· Others
Global epigenetics Market - By Application
· Metabolic Diseases
· Oncology
· Cardiovascular Diseases
· Others
Global Epigenetics Market - By End User
· Academics & Research Institutes
· Contract Research Organizations
· Biotechnology & Pharmaceutical Companies
Global Epigenetics Market - By Geography
o North America
o U.S.
o Canada
o Mexico
o Europe
o U.K.
o Germany
o France
o Asia Pacific (APAC)
o Japan
o China
o India
o Middle East & Africa (MEA)
o South Africa
o UAE
o Saudi Arabia
o South & Central America (SCAM)
o Brazil
Check Sample Report
ABOUT US
The Insight Partners is a one-stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as Technology, Media, and Telecommunication.
Our research model is very simple. We believe in client servicing and delivering the best quality to our customers. Through our research content, we are making sure that our customers get value for their money along with better quality data and analysis.
Our research content is majorly focused towards market trends in terms of market sizing, competitive landscaping, company analysis, regional or country analysis, etc. We provide a detailed break-up of segmentation in terms of geography, technology, products, and services etc., which helps our clients to gain a deeper analytical understanding of various research topics.
CONTACT US
If you have any queries about this report or would like further information, please contact us:
North America: +1 646 491 9876
Email: [email protected]
Epigenetics Market to Grow with Development of Technology, Product, Application, End user and Region 2025
Epigenetics Market to Grow with Development of Technology, Product, Application, End user and Region 2025
According to a new market research study titled ‘Epigenetics Marketto 2025 – Global Analysis and Forecasts by Product, Technology, Application and End User. The global epigenetics market is expected to reach US$ 2,611.57 Mn in 2025 from US$ 991.45 in 2017. The market is estimated to grow with a CAGR of 13.6% from 2018-2025. The report highlights the trends prevalent in the global epigenetics…
View On WordPress
